JMM Profile: Carbapenems: a broad-spectrum antibiotic

J Med Microbiol. 2021 Dec;70(12):001462. doi: 10.1099/jmm.0.001462.

Abstract

Carbapenems are potent members of the β-lactam family that inhibit bacterial cell-wall biosynthesis inhibitors . They are highly effective against Gram-negative and Gram-positive drug-resistant infections . As such, carbapenems are typically reserved as an antibiotic of last resort. The WHO lists meropenem as an essential medicine. Nausea and vomiting are reported in ≤20% of carbapenem recipients, with 1.5% suffering seizures. Enzymatic hydrolysis of the β-lactam ring is the main driver of clinical resistance. These enzymes can be classified as Class A, B and D. Classes A and D are serine β-lactamases, whereas Class B rely on metal-mediated hydrolysis, typically through zinc.

Keywords: antimicrobial resistance; last resort; β-lactams.

Publication types

  • Review

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • Carbapenems* / pharmacology
  • Meropenem / pharmacology
  • beta-Lactamases
  • beta-Lactams

Substances

  • Anti-Bacterial Agents
  • Carbapenems
  • beta-Lactams
  • beta-Lactamases
  • Meropenem